ArticlePloS one2011
Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Human anthrax vaccines: Current status and future prospects.Human vaccines & immunotherapeutics · 2025Review
- Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.Clinical and experimental vaccine research · 2025Article
- Mast cell activators as adjuvants for intranasal mucosal vaccines.International journal of pharmaceutics · 2025Review
- Delivery of small molecule mast cell activators for West Nile Virus vaccination using acetalated dextran microparticles.International journal of pharmaceutics · 2023Article
- Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens.Frontiers in immunology · 2021Article
- Harnessing the Power of Mast Cells in unconventional Immunotherapy Strategies and Vaccine Adjuvants.Cells · 2020Review
- Review
- Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.NPJ vaccines · 2020Article
- Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.Journal of virology · 2019Article
- Identification of Novel Mast Cell Activators Using Cell-Based High-Throughput Screening.SLAS discovery : advancing life sciences R & D · 2019Article
- Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant.Pharmaceutics · 2019Article
- Mast cell activators as novel immune regulators.Current opinion in pharmacology · 2018Review
- Mast cells partially contribute to mucosal adjuvanticity of surfactin in mice.Immunity, inflammation and disease · 2018Article
- Unimpaired Responses to Vaccination With Protein Antigen Plus Adjuvant in Mice With Kit-Independent Mast Cell Deficiency.Frontiers in immunology · 2018Article
- Mucosal vaccine delivery: Current state and a pediatric perspective.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.Clinical and vaccine immunology : CVI · 2016Article
- Roles and relevance of mast cells in infection and vaccination.Journal of biomedical research · 2016Review
- Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Protein & cell · 2015Review
- New era for mucosal mast cells: their roles in inflammation, allergic immune responses and adjuvant development.Experimental & molecular medicine · 2014Review
- Validation of a new 96-well plate spectrophotometric method for the quantification of compound 48/80 associated with particles.AAPS PharmSciTech · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWe previously reported that the immunogenicity of Hcβtre, a botulinum neurotoxin A (BoNT/A) immunogen, was enhanced by fusion to an epithelial cell binding domain, Ad2F, when nasally delivered to mice with cholera toxin (CT). This study was performed to determine if Ad2F would enhance the nasal immunogenicity of Hcβtre in rabbits, an animal model with a nasal cavity anatomy similar to humans. Since CT is not safe for human use, we also tested the adjuvant activity of compound 48/80 (C48/80), a mast cell activating compound previously determined to safely exhibit nasal adjuvant activity in mice.
methodsNew Zealand White or Dutch Belted rabbits were nasally immunized with Hcβtre or Hcβtre-Ad2F alone or combined with CT or C48/80, and serum samples were tested for the presence of Hcβtre-specific binding (ELISA) or BoNT/A neutralizing antibodies.
resultsHcβtre-Ad2F nasally administered with CT induced serum anti-Hcβtre IgG ELISA and BoNT/A neutralizing antibody titers greater than those induced by Hcβtre + CT. C48/80 provided significant nasal adjuvant activity and induced BoNT/A-neutralizing antibodies similar to those induced by CT.
conclusionsAd2F enhanced the nasal immunogenicity of Hcβtre, and the mast cell activator C48/80 was an effective adjuvant for nasal immunization in rabbits, an animal model with a nasal cavity anatomy similar to that in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.